Molecular imaging and theranostics enhance oncologic management via integrated diagnostic and therapeutic modalities. Amid the dynamic and increasingly complex oncologic landscape, the Common Sense ...

The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Whole-body CD8+ T-cell PET imaging can detect spatial and temporal localization of CD8+ T cells. To obtain insight into early CD8+ T-cell response to immunotherapy in patients with melanoma, a highly ...

REPLY: In our recent letter to the editor, we discussed the evolving preclinical testing requirements for PET drugs at the Food and Drug Administration (FDA) ([1][1]). In particular, we highlighted ...

The PSMA-PET Registry for Recurrent Prostate Cancer study was initiated in Ontario, Canada, to provide access to and characterize the performance of 18F-prostate-specific membrane antigen (PSMA) ...

Our objectives were to assess the prognostic value of posttherapy [177Lu]Lu-PSMA (LuPSMA) SPECT/CT by visual evaluation using RECIP 1.0 during LuPSMA therapy and develop an evidence-based clinical ...

Immunohistochemical staining of myocardial GLUT 4 transport protein (green) and nuclei (yellow) (×200) are shown from postischemic circumflex and remote regions from groups 1 and 2. No differences in ...

Malignant gliomas and metastatic tumors are the most common brain tumors. Neuroimaging plays a significant role clinically. In low-grade tumors, neuroimaging is needed to evaluate recurrent disease ...

The field of nuclear cardiology is witnessing growing interest in the use of cardiac PET for the evaluation of patients with coronary artery disease (CAD). The available evidence suggests that ...

Pulmonary hypertension (PH) is a progressive disease with a poor prognosis. Identifying chronic thromboembolic pulmonary disease as a cause of PH has major clinical implications as these patients ...

The use of PET/CT in children has grown substantially in the past few years. There is also an increased interest in keeping the radiation dose to children from CT as low as is clinically practical.

The Centers for Medicare and Medicaid Services (CMS) has provided a mechanism for expanded coverage of selected promising technologies under its “coverage with evidence development (CED)” policy. The ...